Abstract
Heart failure is a common complication associated with type 2 diabetes (T2DM) and the presence of both carries a poorer prognosis. Recent cardiovascular outcome trials have drawn attention to the contrasting effects of the different classes of agents used in the management of T2DM on heart failure outcomes. While SGLT-2 inhibitors and some GLP-1 agonists are associated with improved outcomes with regard to heart failure, thiazolidinediones and certain DPP-4 inhibitors have been shown to increase this risk. In this review article, we will review each of these drug classes and discuss the evidence, if any, for their use in heart failure. Copyright © 2018 John Wiley & Sons.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
